Overview

Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to investigate the efficacy, safety and tolerability of aliskiren 300 mg, 150 mg and 75 mg when compared to ramipril 5 mg in patients with essential hypertension.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Ramipril